Attached files

file filename
EX-99.1 - PHARMACYCLICS INCex991to8k07380_05152014.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 14, 2014
 
PHARMACYCLICS, INC.
(Exact name of registrant as specified in its charter)
     
Delaware
000-26658
94-3148201
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
     
995 E. Arques Avenue, Sunnyvale, California
94085-4521
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (408) 774-0330
 
 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 
 
Item 7.01
Regulation FD Disclosure.
 
On May 14, 2014, Pharmacyclics, Inc., a Delaware corporation (the “Company”), announced that IMBRUVICA® (ibrutinib) will be featured in ten abstracts, including both company-sponsored research studies and investigator-sponsored studies, at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30 through June 3, 2014, in Chicago, IL (the “2014 ASCO Meeting”).
 
A copy of the Company’s Press Release dated May 14, 2014, which contains a number of the abstracts to be presented at the 2014 ASCO Meeting is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
Item 9.01
Financial Statements and Exhibits.
 
(d)    Exhibits.
 
Exhibit No.
 
Description
   
99.1
 
 Press Release dated May 14, 2014
       
 
 
 

 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
 
May 14, 2014
 
PHARMACYCLICS, INC.
 
 
By:
/s/ Manmeet S. Soni
 
Name: Manmeet S. Soni
 
Title:   Chief Financial Officer


 
 

 

EXHIBIT INDEX
 
Exhibit No.
 
Description
   
99.1
 
 Press Release dated May 14, 2014